The nature of biopharma M&A changed dramatically in a year. After a period with no deals over $5 billion, there are now seven or eight such transactions, reflecting a pivot by large pharma to acquire de-risked assets with large market potential to offset looming patent expirations.

Contrary to seeking fully de-risked assets, pharmaceutical companies often prefer acquiring companies with some remaining clinical risk. This strategy allows them to leverage unique insights on early data to acquire assets at a better valuation, creating an opportunity for outsized returns before the value is obvious to others.

Recent biotech deals are setting new valuation records for companies at specific early stages: preclinical (AbbVie/Capstan, ~$2B), Phase 1 (J&J/Halda, $3B), and pre-Phase 3 (Novartis/Abitivi, $12B). This signals intense demand for de-risked innovation well before late-stage data is available.

Contrary to conventional wisdom, pharmaceutical giants don't typically acquire biotechs when their valuations are at rock bottom. Like retail investors, they often wait for positive momentum and a significant stock price increase before engaging, driven by market psychology rather than pure value investing.

The old assumption that small biotechs struggle with commercialization ("short the launch") is fading. Acquirers now target companies like Verona and Intracellular that have already built successful sales operations. This de-risks the acquisition by proving the drug's market viability before the deal, signaling a maturation of the biotech sector.

After a clinical failure, Wrapped Therapeutics in-licensed an antibody from China for $35 million upfront. Just over a year later, without conducting new trials, they were acquired by GlaxoSmithKline for $2.2 billion, showcasing an incredibly rapid and successful turnaround via strategic business development.

GSK's $2.2 billion acquisition of Wrap Therapeutics for a Phase 2b food allergy antibody demonstrates a high-conviction strategy. Instead of a typical licensing deal with milestones and royalties, GSK chose full ownership, indicating immense confidence in the mid-stage asset and a desire to control its entire development and commercial future.

The value of a late-stage asset is not just its scientific promise. Acquirers and investors look for a clear definition of unmet medical need, a straightforward clinical development pathway, and a well-defined regulatory landscape to de-risk the path to market.

Sanofi's $2.2 billion acquisition of Dynavax at a 39% premium highlights the high value placed on companies with approved products and a promising pipeline. This demonstrates the willingness of major pharmaceutical companies to pay significantly above market price to secure de-risked assets and expand strategic portfolios like vaccines.